ARWR - Arrowhead begins dosing in early-stage studies of 2 potential lung disease drugs
- Arrowhead Pharmaceuticals ( NASDAQ: ARWR ) said it dosed the first patients in two phase 1/2a trials of its RNA interference candidates ARO-MUC5AC and ARO-RAGE, being explored to treat certain muco-obstructive and inflammatory pulmonary diseases.
- A phase 1/2a study, dubbed AROMUC5AC-1001, will evaluate ARO-MUC5AC in up to 42 normal healthy volunteers and up to 16 patients with moderate-to-severe asthma.
- Meanwhile, the phase 1/2a trial, called ARORAGE-1001, will evaluate ARO-RAGE in up to 64 healthy people and up to 16 patients with mild-to-moderate asthma.
For further details see:
Arrowhead begins dosing in early-stage studies of 2 potential lung disease drugs